Literature DB >> 33331959

Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer.

Jing Zhao1, Bernd Hamm2, Winfried Brenner3, Marcus R Makowski2,4.   

Abstract

PURPOSE: This study aimed to calculate an applicable relative ratio threshold value instead of the absolute threshold value for simultaneous 68Ga prostate-specific membrane antigen/positron emission tomography ([68Ga]Ga-PSMA-11 PET) in patients with prostate cancer (PCa).
MATERIALS AND METHODS: Our study evaluated thirty-two patients and 170 focal prostate lesions. Lesions are classified into groups according to Prostate Imaging Reporting and Data System (PI-RADS). Standardized uptake values maximum (SUVmax), corresponding lesion-to-background ratios (LBRs) of SUVmax, and LBR distributions of each group were measured based on regions of interest (ROI). We examined LBR with receiver operating characteristic analysis to determine threshold values for differentiation between multiparametric magnetic resonance imaging (mpMRI)-positive and mpMRI-negative lesions.
RESULTS: We analyzed a total of 170 focal prostate lesions. Lesions number of PI-RADS 2 to 5 was 70, 16, 46, and 38. LBR of SUVmax of each PI-RADS scores was 1.5 (0.9, 2.4), 2.5 (1.6, 3.4), 3.7 (2.6, 4.8), and 6.7 (3.5, 12.7). Based on an optimal threshold ratio of 2.5 to be exceeded, lesions could be classified into MRI-positive lesion on [68Ga]Ga-PSMA PET with a sensitivity of 85.2%, a specificity of 72.0%, with the corresponding area under the receiver operating characteristic curve (AUC) of 0.83, p < 0.001. This value matches the imaging findings better.
CONCLUSION: The ratio threshold value of SUVmax, LBR, has improved clinical and research applicability compared with the absolute value of SUVmax. A higher threshold value than the background's uptake can dovetail the imaging findings on MRI better. It reduces the bias from using absolute background uptake value as the threshold value.

Entities:  

Keywords:  Multiparametric MRI; PSMA; Prostate cancer; SUVmax; [68Ga]Ga-PSMA PET/MRI

Year:  2020        PMID: 33331959     DOI: 10.1186/s13244-020-00926-y

Source DB:  PubMed          Journal:  Insights Imaging        ISSN: 1869-4101


  28 in total

1.  Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer.

Authors:  Nadine Woythal; Ruza Arsenic; Carsten Kempkensteffen; Kurt Miller; Jan-Carlo Janssen; Kai Huang; Marcus R Makowski; Winfried Brenner; Vikas Prasad
Journal:  J Nucl Med       Date:  2017-08-03       Impact factor: 10.057

2.  68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters.

Authors:  Stefan A Koerber; Maximilian T Utzinger; Clemens Kratochwil; Claudia Kesch; Matthias F Haefner; Sonja Katayama; Walter Mier; Andrei H Iagaru; Klaus Herfarth; Uwe Haberkorn; Juergen Debus; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-15       Impact factor: 10.057

3.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

4.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

5.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Authors:  Matthias Eiber; Gregor Weirich; Konstantin Holzapfel; Michael Souvatzoglou; Bernhard Haller; Isabel Rauscher; Ambros J Beer; Hans-Jürgen Wester; Juergen Gschwend; Markus Schwaiger; Tobias Maurer
Journal:  Eur Urol       Date:  2016-01-18       Impact factor: 20.096

6.  68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.

Authors:  Wolfgang P Fendler; Dorothea F Schmidt; Vera Wenter; Kolja M Thierfelder; Christian Zach; Christian Stief; Peter Bartenstein; Thomas Kirchner; Franz J Gildehaus; Christian Gratzke; Claudius Faber
Journal:  J Nucl Med       Date:  2016-06-03       Impact factor: 10.057

7.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

8.  Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.

Authors:  Peter Donato; Matthew J Roberts; Andrew Morton; Samuel Kyle; Geoff Coughlin; Rachel Esler; Nigel Dunglison; Robert A Gardiner; John Yaxley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236

9.  Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Authors:  Robert M Hicks; Jeffry P Simko; Antonio C Westphalen; Hao G Nguyen; Kirsten L Greene; Li Zhang; Peter R Carroll; Thomas A Hope
Journal:  Radiology       Date:  2018-09-18       Impact factor: 11.105

10.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.

Authors:  Constantinos Zamboglou; Vanessa Drendel; Cordula A Jilg; Hans C Rischke; Teresa I Beck; Wolfgang Schultze-Seemann; Tobias Krauss; Michael Mix; Florian Schiller; Ulrich Wetterauer; Martin Werner; Mathias Langer; Michael Bock; Philipp T Meyer; Anca L Grosu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

View more
  3 in total

Review 1.  Molecular MR Imaging of Prostate Cancer.

Authors:  Avan Kader; Julia Brangsch; Jan O Kaufmann; Jing Zhao; Dilyana B Mangarova; Jana Moeckel; Lisa C Adams; Ingolf Sack; Matthias Taupitz; Bernd Hamm; Marcus R Makowski
Journal:  Biomedicines       Date:  2020-12-22

2.  Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer.

Authors:  Mathieu Gaudreault; David Chang; Nicholas Hardcastle; Price Jackson; Tomas Kron; Gerard G Hanna; Michael S Hofman; Shankar Siva
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

3.  Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.

Authors:  Jianhua Jiao; Fei Kang; Jingliang Zhang; Zhiyong Quan; Weihong Wen; Xiaohu Zhao; Shuaijun Ma; Peng Wu; Fa Yang; Wei Guo; Xiaojian Yang; Jianlin Yuan; Yongquan Shi; Jing Wang; Weijun Qin
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.